Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Curated Information Page
PubMed Id: 11875080 
Haq R, et al. (2002) Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem 277, 17359-66 11875080
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download Sites

Y368-p - EPOR (human)
Modsite: SEHAQDTyLVLDKWL SwissProt Entrez-Gene
Orthologous residues
EPOR (human): Y368‑p, EPOR (mouse): Y367‑p, EPOR (rat): Y367‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse

T202-p - ERK1 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y204-p - ERK1 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T185-p - ERK2 (human)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y187-p - ERK2 (human)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T183-p - JNK2 (human)
Modsite: ACTNFMMtPYVVTRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y185-p - JNK2 (human)
Modsite: TNFMMTPyVVTRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

T180-p - P38A (human)
Modsite: RHTDDEMtGYVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y182-p - P38A (human)
Modsite: TDDEMTGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y701-p - STAT1 (human)
Modsite: DGPKGTGyIKTELIS SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): Y701‑p, STAT1 iso2 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S727-p - STAT1 (human)
Modsite: TDNLLPMsPEEFDEV SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): S727‑p, STAT1 iso2 (human): , STAT1 (mouse): S727‑p, STAT1 (rat): S727‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase
PD98059 Epo inhibit treatment-induced increase
U0126 Epo inhibit treatment-induced increase
SB202190 Epo inhibit treatment-induced increase

Y705-p - STAT3 (human)
Modsite: DPGSAAPyLKTKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S727-p - STAT3 (human)
Modsite: NTIDLPMsPRTLDSL SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 iso3 (human): , STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase
PD98059 Epo inhibit treatment-induced increase
U0126 Epo inhibit treatment-induced increase

Y694-p - STAT5A (human)
Modsite: LAKAVDGyVKPQIKQ SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S726-p - STAT5A (human)
Modsite: TYMDQAPsPAVCPQA SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): S726‑p, STAT5A (mouse): S725‑p, STAT5A iso2 (mouse): , STAT5A (rat): S725‑p, STAT5A (fruit fly): , STAT5A (sheep): S726‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

Y699-p - STAT5B (human)
Modsite: TAKAVDGyVKPQIKQ SwissProt Entrez-Gene
Orthologous residues
STAT5B (human): Y699‑p, STAT5B (mouse): Y699‑p, STAT5B (rat): Y699‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase

S731-p - STAT5B (human)
Modsite: TYMDQAPsPAVCPQA SwissProt Entrez-Gene
Orthologous residues
STAT5B (human): S731‑p, STAT5B (mouse): S730‑p, STAT5B (rat): S730‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), UT-7 (myeloid)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-3 increase
Epo increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.